by admin | 23rd February 2023 | News
OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to its Scientific Advisory Board World-renowned Ophthalmologist with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Joins Advisory Board of OKYO Pharma London and New York, NY, February...
by admin | 23rd February 2023 | SAB
Dr. Pepose, a specialist in refractive surgery and corneal and external diseases, is the founder and Medical Director of the Pepose Vision Institute and held the Bernard Becker Chair in Ophthalmology and Visual Sciences at Washington University School of Medicine in... by admin | 21st February 2023 | News
OKYO Pharma Limited(“OKYO”, “OKYO Pharma” or the “Company”) OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023. London and New York, NY, February 21, 2023 – OKYO Pharma Limited (LSE: OKYO; NASDAQ:... by admin | 14th February 2023 | News
14 February 2023 OKYO PHARMA LIMITED (“OKYO” or “the Company”) Allotment of Ordinary Shares and Total Voting Rights OKYO Pharma Limited (LSE:OKYO; NASDAQ: OKYO) (the “Company”) today announces that pursuant to an agreement dated 1... by admin | 30th December 2022 | News
London and New York, NY, December 30, 2022 OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market,...
